Key takeaway: Indoco Remedies Limited held its earnings conference call on May 7, 2026, to discuss its financial results for the quarter and year ended March 31, 2026. Management reported a positive performance after six quarters, driven by growth in the international formulations business, particularly in regulated and emerging markets. Standalone net revenues for Q4 FY '26 reached INR 4,291 million, a 25.8% increase year-over-year. The company launched new products and received approvals for ANDAs in the US. However, domestic performance was muted due to seasonal factors. Management acknowledged challenges with receivables and debt levels, attributing the increase in trade receivables to longer collection periods in international markets. The company also announced a strategic decision to hive off its ophthalmology business to focus on core areas. Overall, management expressed confidence in navigating current macroeconomic challenges while aiming for improved operational efficiency.

Key takeaway: Indoco Remedies Limited held its Q3 FY '26 earnings conference call on February 3, 2026, where management reported improved performance in exports and APIs. Highlights included the launch of two new OTC products and a rise in prescription rankings, with the company now ranked 21st in the prescription audit. Standalone net revenues for the quarter were INR 3,896 million, reflecting a 6.8% increase year-over-year, while consolidated revenues reached INR 4,343 million, up 7.9% from the previous year. The API business also showed growth of 24%. Management noted challenges in the domestic acute therapies segment but expressed confidence in secondary sales and prescription responses. The company received an EIR for its Patalganga site following a USFDA audit with zero 483s. Management discussed ongoing efforts to manage costs and improve margins, particularly in the European market, and highlighted the importance of new product introductions for future growth.